Many types of treatments have been FDA approved for lung cancer that focused on different approaches. For examples: Targeted therapies for Alk and EGFR/T790 mutations that targeted specific molecules on the cancer cell; Keytruda focusing on removing cloaks of cancer cells to the immune system; Ketruda plus two other chemos, etc. Targeted therapy has also been re-introduced after the progression on the latest therapy. If those therapies worked for an individual, is there any reason why the treatments process cannot just continuously recycle the previous effective therapies, with the possibility of making stage 4 lung cancer a chronic condition?
Sat, 02/16/2019 - 16:40#1